含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比(1)
摘 要：目的 對比观察含卡培他滨方案一线或后线治疗晚期乳腺癌的效果。方法 选取2013年1月～2016年2月我院收治的95例晚期乳腺癌患者作为研究对象，按照卡培他滨出现方案分为一线组(27例)、二线组(35例)、三线组(33例)，观察其疗效和安全性。结果 治疗效果方面，一线组的完全缓解(CR)、客观有效率(ORR)、临床获益率(CBR)均高于三线组(P<0.05)，疾病进展(PD)低于三线组(P<0.05)；二线组的PD低于三线组(P<0.05)，CBR上高于三线组(P<0.05)。三组安全性比较，差异无统计学意义(P>0.05)。结论 相较于三线方案，一线或二线方案含卡培他滨治疗晚期乳腺癌患者，在控制和缓解患者癌细胞方面具有较好作用；而卡培他滨出现何种方案中并不会增加安全性事件；推荐临床应用一线或二线方案含卡培他滨。
关键词：卡培他滨；乳腺癌；治疗方案；晚期
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.22.041
, 百拇医药
文章编号：1006-1959(2018)22-0142-03
Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy
HU Ping-hua，HUANG Qin，LI Zhi-hua
(Department of Breast Cancer，the Third Hospital of Nanchang，Nanchang 330000，Jiangxi，China)
Abstract：Objective To compare the efficacy of capecitabine regimen in the treatment of advanced breast cancer with first-line or posterior line therapy.Methods 95 patients with advanced breast cancer admitted in our hospital from January 2013 to February 2016 were selected as study subjects.According to capecitabine regimen， the patients were divided into first line group(27 cases)， second line group(35 cases) and third line group(33 cases). The efficacy and safety of capecitabine were observed.Results In terms of therapeutic effect，the complete remission (CR)，objective efficiency rate (ORR)，clinical benefit rate(CBR) of the first group was higher than that in the third line group (P<0.05).The progression of disease (PD) was lower than that of the third line group(P<0.05).The PD of the second line group was lower than that of the third line group(P<0.05) and its CBR was higher than that in the third line group (P<0.05).There was no significant difference in safety among the three groups(P>0.05).Conclusion Compared with the three-line regimen， the first-line or second-line regimen with capecitabine in the treatment of patients with advanced breast cancer，it has a good effect in controlling and relieving cancer cells in patients.And it does not increase security events that which kind of regimen capecitabine was in.It is recommended that the first or second line regimen include capecitabine.
, 百拇医药
Key words：Capecitabine；Breast cancer；Treatment regimen；Advanced stage
乳腺癌(breast cancer)是女性常见恶性肿瘤之一，虽然近几年，早期诊断技术和辅助治疗都有一定的提升，但仍有1/3的患者发展为转移性乳腺癌[1]，而对晚期乳腺癌患者来说，且大部分患者治愈可能性极低，而采用各种手段改善患者生活质量和延长生存期是主要目的。其中放化疗是常见且有效的治疗手段，但是晚期乳腺癌患者在接受各种药物放化疗的过程中，会出现一定的耐药性和抵抗，而这就需要更换治疗方案，不同阶段选择哪种药物进行放化疗具有一定的探讨价值。卡培他滨对肿瘤具有高度选择性，其治疗效果也得到了一定的肯定，但是对于卡培他滨治疗时机的研究较少，基于此，本研究就卡培他滨出现在一线或后线方案的效果进行分析，现将研究结果报告如下。, 百拇医药(胡平华 黄勤 李志华)
关键词：卡培他滨；乳腺癌；治疗方案；晚期
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.22.041
, 百拇医药
文章编号：1006-1959(2018)22-0142-03
Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy
HU Ping-hua，HUANG Qin，LI Zhi-hua
(Department of Breast Cancer，the Third Hospital of Nanchang，Nanchang 330000，Jiangxi，China)
Abstract：Objective To compare the efficacy of capecitabine regimen in the treatment of advanced breast cancer with first-line or posterior line therapy.Methods 95 patients with advanced breast cancer admitted in our hospital from January 2013 to February 2016 were selected as study subjects.According to capecitabine regimen， the patients were divided into first line group(27 cases)， second line group(35 cases) and third line group(33 cases). The efficacy and safety of capecitabine were observed.Results In terms of therapeutic effect，the complete remission (CR)，objective efficiency rate (ORR)，clinical benefit rate(CBR) of the first group was higher than that in the third line group (P<0.05).The progression of disease (PD) was lower than that of the third line group(P<0.05).The PD of the second line group was lower than that of the third line group(P<0.05) and its CBR was higher than that in the third line group (P<0.05).There was no significant difference in safety among the three groups(P>0.05).Conclusion Compared with the three-line regimen， the first-line or second-line regimen with capecitabine in the treatment of patients with advanced breast cancer，it has a good effect in controlling and relieving cancer cells in patients.And it does not increase security events that which kind of regimen capecitabine was in.It is recommended that the first or second line regimen include capecitabine.
, 百拇医药
Key words：Capecitabine；Breast cancer；Treatment regimen；Advanced stage
乳腺癌(breast cancer)是女性常见恶性肿瘤之一，虽然近几年，早期诊断技术和辅助治疗都有一定的提升，但仍有1/3的患者发展为转移性乳腺癌[1]，而对晚期乳腺癌患者来说，且大部分患者治愈可能性极低，而采用各种手段改善患者生活质量和延长生存期是主要目的。其中放化疗是常见且有效的治疗手段，但是晚期乳腺癌患者在接受各种药物放化疗的过程中，会出现一定的耐药性和抵抗，而这就需要更换治疗方案，不同阶段选择哪种药物进行放化疗具有一定的探讨价值。卡培他滨对肿瘤具有高度选择性，其治疗效果也得到了一定的肯定，但是对于卡培他滨治疗时机的研究较少，基于此，本研究就卡培他滨出现在一线或后线方案的效果进行分析，现将研究结果报告如下。, 百拇医药(胡平华 黄勤 李志华)